Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads In Lupus & Connective Tissue Diseases
Lupus & Connective Tissue Diseases for November/December 2015
Lower Extremity Involvement in Systemic Sclerosis, Does SSc impair motion, strength, and agility?
GlycA in Lupus, Is it associated with inflammation?
Immunomodulatory Agent Use During Pregnancy, Studying prescription fill rates
The Genetic Architecture of Lupus, A genome wide association study of the Americas
A Self-efficacy Scale for Systemic Scleroderma, Validating a new tool
Lupus & Connective Tissue Diseases for September/October 2015
Hydroxychloroquine Dosing in Lupus, Comparing weight-based vs ideal body weight dosing
BAFF Gene Expression in Lupus, Comparing its prognostic value to BAFF protein
Metabolome Analysis in Lupus, Associating Kynurenine with mTOR activation
Infections in Patients With Lupus, What contributes to compromised ability to fight?
Racism in Systemic Lupus Erythematosus, Comparing perceptions in African-American and white patients
Lupus & Connective Tissue Diseases for July/August 2015
Tabalumab in Systemic Lupus Erythematosus, Does it block the BAFF pathway?
Mixed Connective Tissue Disease and Lupus, What is their relation with anti-RNP autoantibodies?
SLE in Atlanta, Is there a racial association?
Lupus & Connective Tissue Diseases for May/June 2015
Adherence to SLE Therapies, Correlating nonadherence with ER visits and hospitalizations
Serious Infections Among SLE and LN Patients, Sex, race, and therapies influence infection rates
Breast Cancer Risk for Female Lupus Patients, Is their risk really lower?